We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Mdf5.0
Modafinil Research
Mostly mechanism / observational
18 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Modafinil studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1998–2026 with a typical study size of 209 participants.
Based on 18 studies · 5 meta-analyses · 4 RCTs · 3,612 total participants
Confidence
High confidence
By outcome
Sleepiness & sleep disorders
Mostly mechanism / observational10 studies
Cognition & executive function
Mostly mechanism / observational8 studies
Safety profile
Mostly mechanism / observational5 studies
Focus & attentionSignificantly improves objective wakefulness in narcolepsy, shift-work disorder, and treated OSA; in healthy adults, modest task-dependent cognitive benefit most consistent under demanding/sleep-deprived conditions · Hours per dose; weeks for steady benefit
Too few graded studies2 studies
Active research area
11 studies in the last 5 years · Latest meta-analysis: 2026
199820122026
1Meta-Analysisn=138 · medium study2026
Funding National Institute for Health and Care Research (NIHR303122).
Nourredine M, Jurek L, Hamza T, Cipriani A, Subtil F, Parlatini V, Farhat LC, Veronesi GF, Efthimiou O, Salanti G, Cortese S. · The lancet. Psychiatry (2026)
The 68 RCTs on children and adolescents included 14 138 participants (9981 [70·6%] males and 4157 [29·4%] females) and the 45 RCTs on adults included 11 016 participants (5958 [54·0%] males and 5056 [46·0%] females).
We found no evidence of intransitivity.
Interpretation Our findings challenge both therapeutic inertia-accepting suboptimal response without further dose titration-and uncritical dose escalation beyond licensed limits, when potential harms outweigh expected benefits.
Common fatigue medications provided no improvement in fatigue severity and quality of life.
Rabadi MH, Russell KA, Xu C. · Medical science monitor : international medical journal of experimental and clinical research (2026)
RESULTS Fatigue was present in 134 of 203 (66%) and associated with higher body mass index (30.1±5.5), hyperlipidemia (53.7%), diabetes (16.4%), higher BDI (4.58±4.36) and ESS (10.7±6.51), and worse EQ-5D VAS (all P<0.01).
Strong positive correlations were observed among fatigue (FSS/MFIS), depression (BDI), sleepiness (ESS), and disability (EDSS) scales (P<0.05).
Compared with no medication, fatigue-related medications did not improve FSS/MFIS or EQ-VAS scores; however, modest gains favored treated patients in TFIM change (P=0.04) and 2MWT distance (P=0.02).
By reviewing recent findings from experimental studies, we discussed the beneficial effects of modafinil on several inflammatory diseases, with a particular focus on the underlying mechanisms.
Amini MJ, Seighali N, Arabazadeh Bahri R, Ala M, Mohammad Jafari R, Dehpour AR. · Naunyn-Schmiedeberg's archives of pharmacology (2025)
Fourteen publications were included in our systematic review.
Current evidence supports that modafinil can modulate inflammation, suppress the immune response, and improve disease severity partly by inhibiting NF-κB, NOS, Kca3.1, Kca2.3, and COX-2.
By reviewing recent findings from experimental studies, we discussed the beneficial effects of modafinil on several inflammatory diseases, with a particular focus on the underlying mechanisms.
Trial Registration The study was prospectively registered in the INPLASY database (INPLASY2024120052).
Yan Z, Li J, Yu Y, Qiu S, Wang B, Tang J. · BMC neurology (2025)
Solriamfetol 300 mg was more effective than other treatments in reducing ESS scores (MD = -4.74, 95%CI: -6.51,-2.97) and prolonging sleep latency (MD = 10.82 min, 95%CI: 6.99, 14.31).
There were no considerable differences among drugs in other adverse effects.
Conclusion All of the approved new wake-promoting drugs are effective in controlling narcolepsy symptoms with acceptable adverse effects.
However, the interactions between key neurotransmitters in narcolepsy are still unclear, and challenges remain regarding factors that complicate drug therapy efficacy, necessitating further investigation.
Zhang M, Hu X, Wu H, Fan H. · Frontiers in neurology (2025)
Results The analysis included 5,215 publications, with citations significantly increasing from 1996 to 2024.
Recent interest has surged in medications for excessive daytime sleepiness, such as "Pitolisant", "Modafinil" and "Sodium Oxybate" along with the relationship between narcolepsy and COVID-19.
Conclusion "Pitolisant," "Modafinil," and "Sodium Oxybate" have gained prominence in narcolepsy treatment.
Ultimately, higher quality of evidence may be required to better inform clinical management.
Ghazanfar S, Farooq M, Qazi SU, Chaurasia B, Kaunzner U. · Brain and behavior (2024)
Modafinil leads to a meaningful reduction in fatigue when compared with placebo, as measured by Modified Fatigue Impact Scale [mean difference (MD) = -4.42 [-8.01, -.84]; I 2 = 45%; p = .02] and Epworth Sleepiness Scale [MD = -.87 [-1.64, -.10]; I 2 = 0%; p = .03].
Modafinil also demonstrated a greater risk of precipitating adverse events (e.g., insomnia, gastrointestinal symptoms) when compared with placebo [RR = 1.30 [1.03, 1.66]; I 2 = 0%; p = .03].
In quality-of-life assessments, modafinil was associated with overall improvement in well-being [standardized mean difference = .18 [.01, .35]; I 2 = 56%; p = .04].
However, long-term efficacy and safety remain to be established, underscoring the need for larger, long-duration randomized trials.
Mann GS, Ramakrishnan M, Pakkam ML, Sufiyan N, Kukadiya R, Girigosavi KB. · Sleep medicine: X (2026)
Modafinil significantly improved MWT scores (MD = 3.56, 95% CI [2.25-4.86]) and reduced ESS scores (MD = -3.34, 95% CI [-4.13 to -2.56]).
Moderate heterogeneity was observed but was reduced following pre-specified sensitivity analyses.
Conclusion These findings confirm the short-term efficacy of modafinil in reducing excessive daytime sleepiness based on legacy randomized controlled trials conducted primarily in the 1990s and early 2000s, while highlighting the absence of new eligible RCTs in the past decade.
We address ethical, societal, and regulatory concerns, especially those relating to non-medical use, highlighting the importance of responsible development and precision-based approaches in cognitive therapeutics.
Zhang M et al. · Drug discovery today (2026)
This review explores both established and emerging CEDs that target neurotransmitter systems, neuroinflammation, and neuroplasticity.
It discusses innovative design strategies, such as multi-target agents and prodrugs, and examines clinical challenges in Alzheimer's disease and other conditions.
We address ethical, societal, and regulatory concerns, especially those relating to non-medical use, highlighting the importance of responsible development and precision-based approaches in cognitive therapeutics.
Naguy A et al. · Psychopharmacology bulletin (2026)
Herein, authors would touch briefly on the current available literature on eugeroics as germane to psychiatric practice whilst examining the extant evidence.
Both doses of modafinil significantly improved sleep latency on the Maintenance of Wakefulness Test versus placebo, confirming it is a useful adjunct for residual sleepiness in nCPAP-treated OSA.
Black, Hirshkowitz · Sleep (2005)
12-week, multicenter, double-blind, placebo-controlled RCT of modafinil 200 or 400 mg as adjunct in CPAP-treated OSA with residual sleepiness
Both doses significantly improved objective wakefulness (MWT), Epworth scores, and clinical global impression
Did not adversely affect nighttime sleep or CPAP adherence
There was an overall effect of modafinil (SMD=0.12) … there is a user perception that these drugs are effective cognitive enhancers, but this is not supported by the evidence so far.
Roberts, Jones, Sumnall, Gage, Montgomery · European neuropsychopharmacology (2020)
Meta-analysis pooling 14 modafinil studies (64 effect sizes) in healthy non-sleep-deprived adults vs placebo
Overall effect small (SMD=0.12); a significant benefit only for memory updating (SMD=0.28)
Concludes the popular cognitive-enhancer reputation outruns the evidence
Modafinil exhibits robust effects on catecholamines, serotonin, glutamate, GABA, orexin, and histamine systems, and at well-tolerated doses improves working and episodic memory; it appears well-tolerated with a low liability to abuse.
Minzenberg, Carter · Neuropsychopharmacology (2008)
Comprehensive review of modafinil's neurochemistry and cognitive effects across animals, healthy adults, and patients
Wake-promotion is driven by cortical catecholamine effects, engaging orexin and histamine arousal systems
Improves prefrontal-dependent cognition (working/episodic memory) at well-tolerated doses
When more complex assessments are used, modafinil appears to consistently engender enhancement of attention, executive functions, and learning. Importantly, we did not observe any preponderances for side effects or mood changes.
Battleday RM, Brem AK. · European Neuropsychopharmacology (2015)
MODAFINIL (parent), NOT FLADRAFINIL: a systematic review of modafinil for cognitive neuroenhancement in healthy non-sleep-deprived adults — included here to show what the RELATED drug does, not what fladrafinil does
Found modest, task-dependent benefits to attention, executive function and learning with modafinil, especially on more complex tasks
Cited by fladrafinil vendors as if it were fladrafinil evidence — it is NOT; fladrafinil is a different fluorinated analogue/prodrug with no human cognition trials
Treatment with modafinil resulted in significant improvement in two objective measures of EDS ... The most frequent adverse experience was headache ... The data indicate that modafinil has an excellent safety profile and is very well tolerated.
US Modafinil in Narcolepsy Multicenter Study Group. · Neurology (2000)
MODAFINIL (parent), NOT FLADRAFINIL: a large multicenter randomized placebo-controlled trial of modafinil for excessive daytime somnolence in narcolepsy — parent-drug human evidence
Modafinil improved objective wakefulness vs placebo; the most frequent adverse event was headache — the kind of symptom extrapolated to fladrafinil
Reinforces the modafinil-class effect AND its typical adverse-event profile in supervised humans, for the PARENT compound only